Journal of Clinical Endocrinology & Metabolism, Vol 63, 651-655, Copyright © 1986 by Endocrine Society

ARTICLES

Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age

K Tan and RC Baxter

Despite reports of reduced serum insulin-like growth factor (IGF) levels in experimentally diabetic animals, human diabetic patients have been reported to have decreased, normal, or even elevated levels. This study was a cross-sectional examination of the effect of age on immunoreactive IGF-I levels in adult patients with insulin-dependent or noninsulin-dependent diabetes mellitus (IDDM and NIDDM) attending a diabetes out-patient clinic. The patients and normal subjects studied were divided into the age ranges 21-30, 31-40, 41-50, 51-60, and over 60 yr. For all ages combined, the mean IGF-I level (+/- SD) was 0.84 +/- 0.26 U/ml (202 +/- 62 ng/ml) in 133 normal subjects, significantly reduced to 0.41 +/- 0.17 U/ml in 121 IDDM patients, and 0.49 +/- 0.19 U/ml in 46 NIDDM patients (both P less than 0.001). In both groups there was a marked decline in IGF-I with increasing age (P less than 0.01). Except for NIDDM patients aged 21-30 yr (only two patients), IGF- I levels in both IDDM and NIDDM patients were significantly lower in every age range than those in age-matched normal subjects, but did not differ between the two diabetic groups. Glycosylated hemoglobin levels correlated inversely with IGF-I levels only in younger patients with IDDM (r = -0.486; P less than 0.05 for patients aged 21-40 yr). We conclude that factors common to IDDM and NIDDM, perhaps related to relative nutritional deficiency at the cellular level, cause a reduction in serum IGF-I levels, and that this reduction occurs independently of age-related changes in IGF-I.

This article has been cited by other articles:

				J. Ren, J. Duan, D. P. Thomas, X. Yang, N. Sreejayan, J. R. Sowers, A. Leri, J. Kajstura, F. Gao, and P. Anversa IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R793 - R802. [Abstract] [Full Text] [PDF]

				M. Yazdanpanah, F. A Sayed-Tabatabaei, J. A M J L Janssen, I. Rietveld, A. Hofman, T. Stijnen, H. A P Pols, S. W J Lamberts, J. C M Witteman, and C. M van Duijn IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. Eur. J. Endocrinol., November 1, 2006; 155(5): 751 - 756. [Abstract] [Full Text] [PDF]

				C. A. Hedman, J. Frystyk, T. Lindstrom, J.-W. Chen, A. Flyvbjerg, H. Orskov, and H. J Arnqvist Residual {beta}-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6305 - 6309. [Abstract] [Full Text] [PDF]

				R. E. Schmidt, D. A. Dorsey, L. N. Beaudet, and R. G. Peterson Analysis of the Zucker Diabetic Fatty (ZDF) Type 2 Diabetic Rat Model Suggests a Neurotrophic Role for Insulin/IGF-I in Diabetic Autonomic Neuropathy Am. J. Pathol., July 1, 2003; 163(1): 21 - 28. [Abstract] [Full Text] [PDF]

				A. Nishiyama, D. N. Ishii, P. H. Backx, B. E. Pulford, B. R. Birks, and M. M. Tamkun Altered K+ channel gene expression in diabetic rat ventricle: isoform switching between Kv4.2 and Kv1.4 Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1800 - H1807. [Abstract] [Full Text] [PDF]

				N. Vaessen, P. Heutink, J. A. Janssen, J. C. M. Witteman, L. Testers, A. Hofman, S. W. J. Lamberts, B. A. Oostra, H. A. P. Pols, and C. M. van Duijn A Polymorphism in the Gene for IGF-I: Functional Properties and Risk for Type 2 Diabetes and Myocardial Infarction Diabetes, March 1, 2001; 50(3): 637 - 642. [Abstract] [Full Text]

				K.-C. Leung, N. Doyle, M. Ballesteros, M. J. Waters, and K. K. Y. Ho Insulin Regulation of Human Hepatic Growth Hormone Receptors: Divergent Effects on Biosynthesis and Surface Translocation J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4712 - 4720. [Abstract] [Full Text]

				R. E. Schmidt, D. A. Dorsey, L. N. Beaudet, S. B. Plurad, C. A. Parvin, and M. S. Miller Insulin-like Growth Factor I Reverses Experimental Diabetic Autonomic Neuropathy Am. J. Pathol., November 1, 1999; 155(5): 1651 - 1660. [Abstract] [Full Text] [PDF]

				V. Quarmby, C. Quan, V. Ling, P. Compton, and E. Canova-Davis How Much Insulin-Like Growth Factor I (IGF-I) Circulates? Impact of Standardization on IGF-I Assay Accuracy J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1211 - 1216. [Abstract] [Full Text]

				H.-X. Zhuang, L. Wuarin, Z.-J. Fei, and D. N. Ishii Insulin-Like Growth Factor (IGF) Gene Expression Is Reduced in Neural Tissues and Liver from Rats with Non-Insulin-Dependent Diabetes Mellitus, and IGF Treatment Ameliorates Diabetic Neuropathy J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 366 - 374. [Abstract] [Full Text]

				N.-y. Chen, W. Y. Chen, and J. J. Kopchick Liver and Kidney Growth Hormone (GH) Receptors Are Regulated Differently in Diabetic GH and GH Antagonist Transgenic Mice Endocrinology, May 1, 1997; 138(5): 1988 - 1994. [Abstract] [Full Text] [PDF]

				K. Thrailkill, T. Quattrin, L. Baker, J. Litton, K. Dwigun, M. Rearson, M. Poppenheimer, D. Kotlovker, D. Giltinan, N. Gesundheit, et al. Dual Hormonal Replacement Therapy with Insulin and Recombinant Human Insulin-Like Growth Factor (IGF)-I in Insulin-Dependent Diabetes Mellitus: Effects on the Growth Hormone/IGF/IGF-Binding Protein System J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1181 - 1187. [Abstract] [Full Text] [PDF]